Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27045311 | 0.98 | USP2 (0.52) | HPGDSMN1; SMN2USP2ALDH1A1MEN1 | |
| SCHEMBL8210703 | 0.87 | KMT2A (0.55) | SMN1; SMN2ALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL2862442 | 0.82 | ALDH1A1 (0.60) | SMN1; SMN2ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL18608789 | 0.81 | MEN1 (0.58) | SMN1; SMN2HTTMEN1KMT2ANPSR1 | |
| SCHEMBL13925211 | 0.81 | CD4 (0.47) | ALDH1A1MEN1KMT2AGPR119TSHR | |
| SCHEMBL20058376 | 0.80 | CYP2D6 (0.48) | SMN1; SMN2USP2ALDH1A1MEN1KMT2A | |
| SCHEMBL1722245 | 0.79 | SMN1; SMN2 (0.57) | SMN1; SMN2USP2ALDH1A1HTTMEN1 | |
| SCHEMBL18785460 | 0.79 | MGLL (0.58) | USP2ALDH1A1TSHROPRD1OPRK1 | |
| SCHEMBL3863834 | 0.78 | KMT2A (0.63) | HPGDSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL20274773 | 0.78 | TP53 (0.50) | MEN1KMT2AGPR119TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10022359-B2 | 1,9-diazaspiro undecane compounds having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2018-07-17 | — | — | US | disclosed |
| US-20170354648-A1 | 1,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170354648-A1 | 1,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRD1, OPRM1, SIGMAR1 | HPGD 1047/4885SMN1; SMN2 821/4885USP2 1187/4885 |
| US-10022359-B2 | 1,9-diazaspiro undecane compounds having multimodal activity against pain | OPRD1, OPRM1, SIGMAR1 | HPGD 1047/4885SMN1; SMN2 821/4885USP2 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.